Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Tymlos (abaloparatide) is a human parathyroid hormone–related peptide [PTHrP(1-34)] analog indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It is also approved to increase bone density in men with osteoporosis at high risk for fracture. Abaloparatide activates the parathyroid hormone 1 receptor (PTH1R), stimulating osteoblastic activity and increasing bone formation. Clinical trials have demonstrated significant reductions in the risk of vertebral and nonvertebral fractures with Tymlos use.
Fact Table | |
Formula | C174H300N56O49 |
License | US FDA (2017) |
Bioavailability | 36% (subcutaneous) |
Legal status | Prescription only |
Chemical Name | Abaloparatide |
Elimination half-life | ~1 hour |
Dosage (Strength) | 80 mcg/0.4 mL solution in a prefilled pen |
Pregnancy | Not recommended – potential risk to fetus |
Brands | Tymlos |
Protein binding | Not extensively protein bound |
PubChem CID | 25070907 |
MedlinePlus | a617007 |
ChEBI | 146324 |
ATC code | H05AA05 |
DrugBank | DB13928 |
KEGG | D10985 |
Routes of administration | Subcutaneous injection |
Tymlos is administered by subcutaneous injection in the periumbilical region of the abdomen.
Supplementation with calcium and vitamin D is advised as needed to maintain adequate levels during therapy.
Active ingredient: abaloparatide (80 mcg/40 mcL) Inactive ingredients: phenol, acetic acid, sodium acetate trihydrate, and water for injection
Each 3 mL prefilled pen delivers 30 doses and should be stored refrigerated prior to first use; once in use, it may be kept at room temperature for up to 30 days.
Tymlos is contraindicated in patients with:
Tymlos may cause transient hypercalcemia; serum calcium should be monitored, especially when used alongside calcium supplements. Use with caution in patients with renal impairment. As with other anabolic bone therapies, Tymlos carries a boxed warning for a potential risk of osteosarcoma based on animal studies—its use is restricted to patients for whom benefits outweigh risks. Orthostatic hypotension has been reported shortly after injection, particularly during the first few doses.
Common side effects may include:
Serious adverse events may include orthostatic hypotension and potential increased risk of osteosarcoma (observed in animal studies, not confirmed in humans).